Prescient Therapeutics Limited
PTX.ASXHealth Care
Bio-pharmaceutical research and development investment.
Market Data
$0.077
-0.0%$82.0M
-100000.0x
$-0.010
0.00%
-0.1%
Latest Earnings
Appendix 4D and Half Year Financial Report
24 February 2026
Prescient Therapeutics reported a half-year loss of $4.0M, a 62.8% increase from the prior corresponding period, despite successfully raising $9.8M through placement and share purchase plan. The biotechnology company achieved significant clinical progress with its PTX-100 cancer therapy, including completion of Phase 1b trials showing 43% response rates and activation of nine clinical sites for Phase 2a trials. Key points: Successful capital raise of $9.8M through placement ($3.0M) and share purchase plan ($6.9M); PTX-100 Phase 1b trial achieved 43% overall response rate with 100% clinical benefit rate in r/rCTCL patients; Phase 2a clinical trial progressing with nine sites activated (six US, three Australian) and six patients enrolled
Recent Announcements
Appendix 4D and Half Year Financial Report
Prescient Therapeutics reported a half-year loss of $4.0M, a 62.8% increase from the prior corresponding period, despite successfully raising $9.8M through placement and share purchase plan. The biotechnology company achieved significant clinical progress with its PTX-100 cancer therapy, including completion of Phase 1b trials showing 43% response rates and activation of nine clinical sites for Phase 2a trials. Key points: Successful capital raise of $9.8M through placement ($3.0M) and share purchase plan ($6.9M); PTX-100 Phase 1b trial achieved 43% overall response rate with 100% clinical benefit rate in r/rCTCL patients; Phase 2a clinical trial progressing with nine sites activated (six US, three Australian) and six patients enrolled
Get real-time alerts for PTX
Receive AI-powered earnings summaries and instant notifications when Prescient Therapeutics Limited releases results.
Register Free